Agent is idle (waiting for messages). agent_id: 0b65d3f3-10e6-4f63-8d2e-39e018ccf197, agent_type: code-review, status: idle, description: Final mock review round 4, elapsed: 621s, total_turns: 1, model: gpt-5.6-sol

[Turn 0]
I cannot write `C:\Users\Gary\Desktop\jepa\autopilot\reports\P18_final_review.md` because this review session is read-only. The full review is provided below.

**Accept probability:** [INFERRED] **18%**  
**Trend:** [INFERRED] **18% -> 34% -> 22% -> 15% -> 18%**  
**Contradictions remain:** [MEASURED] **Yes.** The original COVER stopping contradiction is fixed, but several material inconsistencies remain.  
**Highest-value remaining fix:** [INFERRED] **Reconcile the primary and label-efficiency probe protocols before freezing.** The alternative probe fit shrinks the epoch-100 CENTROID advantage from `+0.0109` to `+0.0038` and changes COVER from `0.8577` to `0.8785`; this currently undermines the surviving headline.

---

# P18 Final Review — GenAI4Health @ NeurIPS 2026

## Review basis

[MEASURED] This panel uses the same methodology/statistics, clinical relevance, and novelty/presentation rubric and the same 1–10 scoring and acceptance-probability scale as rounds 1–3 and the blind review.

[MEASURED] The reviewed PDF is 26 pages total; the main paper ends on page 9 and references begin on page 10. The former red ANATOMY-V2 placeholders are gone, epoch 100 renders as not run, and the PDF contains no use of the former ORACLE display name.

[MEASURED] The new clean ANATOMY-V2 epoch-75 artifact reports test AUC `0.861246`. The matched statistics report `-0.0111` versus RANDOM, CI `[-0.0181,-0.0042]`, and `p=0.0017`.

## Round-4 repair verification

| Change | Verdict | Evidence |
|---|---|---|
| Clean ANATOMY-V2 epoch 75 | [INFERRED] Genuine scientific repair, incompletely integrated | [MEASURED] The clean fp32 value agrees across the named result artifact, `SOURCES.md`, Table 1, and generated macros. [MEASURED] The Discussion and Conclusion nevertheless continue to describe anatomy-shaped masking as indistinguishable from RANDOM and say harm cannot be claimed, without acknowledging the significant epoch-75 deficit. |
| ANATOMY-V2 stopped at epoch 75 | [INFERRED] Transparently disclosed but scientifically indefensible for a long-horizon comparison | [MEASURED] The paper says training was stopped because the test-set deficit was significant and another 25 epochs “would have deepened” it. [INFERRED] That is an outcome-dependent stopping decision, and the asserted future trajectory was not observed. |
| CENTROID rename | [INFERRED] Fully repaired | [MEASURED] The PDF consistently uses CENTROID and explains that it uses an intensity-weighted centroid without segmentation or labels. |
| ENVELOPE/COVER naming | [INFERRED] Partly repaired | [MEASURED] COVER now states that its name describes intent. [MEASURED] ENVELOPE still appears as “random-within-retina,” while the Abstract, Discussion, Conclusion, and figure captions still say “restricting” or placing rectangles “on tissue,” despite measured purity of only `43.5%`. |
| COVER chronology | [INFERRED] Substantially repaired | [MEASURED] Setup, Results, and Limitations now agree that COVER reaches epoch 100. [MEASURED] Other stale COVER-related statements remain, including the Table 1 claim that no fp32 epoch-75 null exists and the claim that COVER was the only segmenter-driven policy taken to the full horizon. |
| Retracted-run identity | [INFERRED] Incompletely repaired | [MEASURED] Appendix D correctly calls the four runs unguided null controls. Appendix C still calls them “four retracted coverage probes.” |
| Label-efficiency appendix | [INFERRED] Useful question, but the current experiment exposes a major protocol-sensitivity problem | [MEASURED] The appendix reports the requested low-label measurements. [MEASURED] Its probe-training procedure is not the primary protocol, and its full-label results disagree substantially with Table 1. |
| Subgroup operating points | [INFERRED] Useful but not a same-false-positive-rate comparison | [MEASURED] The shared-threshold subgroup values and intervals agree with the named artifact. [MEASURED] CENTROID’s higher sensitivity accompanies lower overall test specificity, and the appendix elsewhere still says no subgroup sensitivity or threshold-transfer analysis was performed. |

# Reviewer 1 — Statistics and experimental methodology

## Summary

[MEASURED] The new clean epoch-75 ANATOMY-V2 result is real and precision matched. [INFERRED] It strengthens the observation that this implemented anatomy arm underperformed, but it still cannot identify anatomical precision as the cause because masking budget, context, loss slots, and collation differ simultaneously. [INFERRED] Single-run pretraining, outcome-dependent stopping, and newly exposed probe-protocol sensitivity prevent policy-level conclusions.

## Score and recommendation

- **Score:** [INFERRED] **3/10**
- **Recommendation:** [INFERRED] **Reject**
- **Confidence:** [INFERRED] **5/5**

## Strengths

1. [MEASURED] The epoch-75 result is cleanly sourced from the shared-ancestor fp32 continuation and replaces, rather than reuses, the precision-spliced run.

2. [MEASURED] Case-level inference uses identical test subjects, paired resampling, and correlated-ROC tests. The paper correctly states that this quantifies uncertainty for fixed score vectors rather than pretraining variance.

3. [MEASURED] Precision is no longer a plausible explanation for the principal arm differences: Appendix M reports observed fp16/fp32 changes below `0.0002`.

4. [MEASURED] The paper explicitly discloses the cross-family collation difference and the adaptive reuse of the test split.

## Weaknesses

1. **[FATAL] [MEASURED] Every masking policy still has one pretraining continuation.**  
   [INFERRED] The roughly `0.011` headline is credible as a difference between these two stored test-score vectors, but not as an expected masking-policy effect. Correlated checkpoints and repeated linear heads do not substitute for independent continuation seeds.

2. **[MAJOR] [MEASURED] ANATOMY-V2 was stopped after inspecting an unfavorable test result.**  
   [MEASURED] The paper states that the arm moved from `+0.0013` at epoch 50 to `-0.0111` at epoch 75 and was stopped because another 25 epochs “would have deepened” the deficit.  
   [INFERRED] This is not a defensible scientific stopping rule. An encoder trajectory may recover, and the claim about epoch 100 is counterfactual. The disclosure is adequate, but disclosure does not remove selective-horizon bias.

3. **[MAJOR] [MEASURED] The label-efficiency experiment uses a materially different probe-fitting protocol and changes the central result.**  
   [MEASURED] Table 1 reports epoch-100 AUCs of `0.8746` for RANDOM, `0.8855` for CENTROID, and `0.8577` for COVER. Appendix G’s full-label row reports `0.8811`, `0.8850`, and `0.8785`, respectively. Its CENTROID–RANDOM margin is therefore `+0.0038`, not `+0.0109`.  
   [MEASURED] `C:\Users\Gary\Desktop\jepa\autopilot\p5_label_efficiency.py` fits a full-batch head for 200 epochs at learning rate `0.05` without validation selection, whereas the primary probe uses mini-batches, learning rate `0.0004`, warmup/cosine scheduling, and validation-selected early stopping.  
   [INFERRED] The appendix is not a label-fraction extension of the primary protocol. More importantly, it suggests that the apparent guidance advantage is strongly dependent on head optimization.

4. **[MAJOR] [MEASURED] The controlled-intervention premise remains false.**  
   [MEASURED] The Abstract says the policies differ only in target placement, and the setup says the only difference is the mask sampler. The paper later acknowledges that anatomy targets are fixed to `K=16` while rectangle arms use a different collation path, changing masking ratio, visible context, loss slots, and spatial truncation.  
   [INFERRED] The study does not isolate location from shape or anatomical precision.

5. **[MAJOR] [MEASURED] H2 is still argued using invalid transitive non-significance logic.**  
   [MEASURED] The paper says an arm that does not separate from RANDOM “cannot exceed” ENVELOPE, so no direct contrast is required. Failure to reject one contrast cannot establish another contrast.  
   [MEASURED] The generated statistics artifact already contains direct matched ANATOMY-V2-versus-ENVELOPE contrasts at epochs 50 and 75.  
   [INFERRED] The direct contrast should be reported, while still being described as a confounded single-continuation comparison.

6. **[MAJOR] [MEASURED] The test split was adaptively reused.**  
   [MEASURED] Policies, checkpoints, analyses, and now the stopping horizon were chosen after repeated test inspection.  
   [INFERRED] Multiplicity correction over a final table does not account for this research-program-level selection. The paper appropriately calls the statistics descriptive, but the title, hypotheses, and Conclusion remain confirmatory in tone.

# Reviewer 2 — Clinical and health-AI relevance

## Summary

[MEASURED] The paper now contains label-efficiency and deployed-threshold analyses directly relevant to medical screening. [INFERRED] These additions are useful exploratory diagnostics, but neither establishes clinical benefit: the label-efficiency protocol differs from the primary evaluation, and the operating-point gain is not measured at equal realized false-positive rates. [INFERRED] One reused FairVision split remains too narrow for a general health-AI masking recommendation.

## Score and recommendation

- **Score:** [INFERRED] **4/10**
- **Recommendation:** [INFERRED] **Weak Reject**
- **Confidence:** [INFERRED] **4/5**

## Strengths

1. [MEASURED] At 5% of labels, Appendix G reports CENTROID `0.8108` versus RANDOM `0.7925`, a mean difference of `+0.0183`.

2. [MEASURED] The subgroup operating-point appendix reports one threshold, paired sensitivity intervals, and positive counts, rather than presenting subgroup point estimates as definitive evidence.

3. [MEASURED] The White sensitivity change is `+0.0343`, CI `[+0.0194,+0.0491]`, while the Black change is `+0.0037`, CI `[-0.0261,+0.0336]`. The paper explicitly treats this as unresolved power rather than evidence that Black patients do not benefit.

4. [MEASURED] The paper states that the models are not clinically validated or intended for deployment.

## Weaknesses

1. **[MAJOR] [MEASURED] The operating-point gain is not at the same realized false-positive rate.**  
   [MEASURED] At the shared numeric threshold, RANDOM has test specificity `0.8794` and CENTROID `0.8696`. CENTROID’s overall sensitivity increase from `0.7162` to `0.7428` therefore accompanies an increased false-positive rate.  
   [INFERRED] The text’s “two to three more cases detected per hundred at the same false-positive rate” interpretation remains unsupported.

2. **[MAJOR] [MEASURED] The shared threshold is selected from RANDOM validation scores and then applied to a separately fitted CENTROID head.**  
   [INFERRED] Raw sigmoid scores from separately trained heads are not automatically on a common decision scale. A clinically meaningful comparison should use separately validation-selected thresholds targeting the same operating criterion, then report the transferred sensitivity and specificity jointly.

3. **[MAJOR] [MEASURED] The threshold analysis omits the corresponding subgroup specificity changes from the displayed comparison.**  
   [MEASURED] In the named artifact, White sensitivity increases while White specificity changes by approximately `-0.0162`.  
   [INFERRED] Reporting sensitivity alone can make a threshold trade-off look like pure benefit.

4. **[MAJOR] [MEASURED] The label-efficiency claim lacks paired-difference uncertainty.**  
   [MEASURED] Five repeated AUCs are reduced to per-arm means and standard deviations; repeat-level paired differences are not saved or reported.  
   [INFERRED] The statements that the advantage is largest at 5% and has “closed to noise” by 10% are suggestive descriptions, not established label-fraction interactions.

5. **[MAJOR] [MEASURED] External validity remains extremely narrow.**  
   [MEASURED] There is one dataset, one glaucoma label, one segmentation model, one test split, and no independent scanner, population, disease, or dense retinal task.  
   [INFERRED] The surviving evidence supports an OCT case study, not a general conclusion about anatomy-guided medical pretraining.

# Reviewer 3 — Novelty, presentation, and auditability

## Summary

[INFERRED] A candid negative case study and masking-pipeline failure analysis could fit this workshop. [MEASURED] The final artifact is now page-compliant, the CENTROID name is honest, and the former red placeholders are gone. [INFERRED] However, the manuscript still contains enough stale and incompatible claims that it does not read as a frozen authoritative record.

## Score and recommendation

- **Score:** [INFERRED] **4/10**
- **Recommendation:** [INFERRED] **Reject**
- **Confidence:** [INFERRED] **5/5**

## Remaining internal contradictions

1. **ANATOMY-V2 interpretation**  
   [MEASURED] Table 1 and the stopping rationale say ANATOMY-V2 is significantly below RANDOM at epoch 75. The Discussion says anatomy-shaped masking cannot be called harmful and is indistinguishable from RANDOM; the Conclusion repeats that it “left performance indistinguishable.”  
   [INFERRED] The new result was inserted into the table without updating the paper’s central interpretation.

2. **Epoch-75 precision**  
   [MEASURED] Table 1’s caption says no fp32 RANDOM null exists at epoch 75. Appendix M and the evidence inventory contain that fp32 null, and the text later says every contrast is precision matched.  
   [INFERRED] This is the same stale precision contradiction identified previously.

3. **Matched compute**  
   [MEASURED] The Conclusion says the comparison used matched compute, while ANATOMY-V2 stops at epoch 75 and three principal arms reach epoch 100.  
   [INFERRED] Compute is matched only at common checkpoints, not across the reported training horizons.

4. **Held-out test set**  
   [MEASURED] The Data section says no test volume is seen during model selection. The Limitations state that policies, checkpoints, and analyses were chosen after repeated inspection of that test split, and the ANATOMY-V2 stopping decision was also based on its test result.  
   [INFERRED] The broad “no model selection” statement is false unless narrowed specifically to probe-head selection.

5. **Probe inventory**  
   [MEASURED] Contributions still says “21 frozen probes,” the subgroup analysis uses 22, and the current primary inventory contains 31 rows before excluded and retracted runs.  
   [INFERRED] The old count remains stale.

6. **Retracted-run identity**  
   [MEASURED] Appendix C calls the four excluded runs “coverage probes.” Appendix D correctly explains that they are unguided RANDOM controls whose directory names came from a coverage campaign.  
   [INFERRED] The claimed factual correction was applied in only one location.

7. **Subgroup audit scope**  
   [MEASURED] Appendix C and the ethics appendix say the audit includes no subgroup sensitivity, calibration, or threshold-transfer analysis. Appendix I contains subgroup sensitivity at a transferred threshold and subgroup calibration values in the named artifact.  
   [INFERRED] The new appendix was not propagated into the limitations text.

8. **ENVELOPE framing**  
   [MEASURED] The measured purity is `43.5%`, and the Results correctly say aiming is not containment. The Abstract, Discussion, Conclusion, method parenthetical, and figures still use “restricting,” “random-within-retina,” or “on tissue.”  
   [INFERRED] The naming repair is partial and remains misleading in the most visible sections.

9. **COVER description**  
   [MEASURED] The Results call COVER the only segmenter-driven policy continued to epoch 100. ENVELOPE is explicitly segmenter-guided and also reaches epoch 100.  
   [INFERRED] This factual statement remains wrong.

10. **Provenance guarantee**  
    [MEASURED] The paper, `C:\Users\Gary\Desktop\jepa\paper\genai4health2026\SOURCES.md`, and `C:\Users\Gary\Desktop\jepa\HANDOFF.md` claim every quantity is macro-generated so prose and tables cannot disagree. The source still contains literal empirical counts and percentages, including the stale 21-probe count and multiple mask-geometry values.  
    [INFERRED] The guarantee should be removed or made true; the current contradictions demonstrate that the gate does not provide the assurance claimed.

## Novelty judgment

[MEASURED] The paper’s related-work appendix itself concludes that the direction of the masking result is not new.

[INFERRED] The workshop-level novelty could lie in the OCT setting, shared ancestor, direct comparison with a trained segmenter, and the implementation postmortem. That is sufficient for consideration as an explicitly exploratory case study, but not for the current “Location Beats Shape” causal framing.

# Meta-review

## Decision

**[INFERRED] Reject in its current form.**

## Does stopping ANATOMY-V2 at epoch 75 look defensible?

[INFERRED] No, not for the paper as currently framed.

[MEASURED] The reason is disclosed clearly, so the decision does not look hidden. [INFERRED] That candor helps trust, but the rationale remains outcome-dependent stopping on an adaptively reused test split. The paper did not preregister a futility boundary, estimate continuation variance, or establish that an epoch-100 recovery was impossible. Saying the next 25 epochs “would have deepened” the deficit converts an expectation into an unmeasured result.

[INFERRED] The epoch-75 point is valid as an exploratory checkpoint observation. It is not a substitute for a matched epoch-100 endpoint, and it cannot support “matched compute” or a definitive best-policy ranking.

## Is the surviving contribution sufficient for a workshop?

[INFERRED] Potentially, but not in this version.

- [MEASURED] CENTROID exceeds RANDOM by `+0.0109` under the primary epoch-100 probe.
- [MEASURED] ENVELOPE exceeds RANDOM by `+0.0120` at epoch 50 and `+0.0062` at epoch 100 under the PDF’s primary fp16 contrasts.
- [MEASURED] The clean ANATOMY-V2 arm is `-0.0111` below RANDOM at epoch 75.
- [MEASURED] Four rectangle-arm geometry measurements do not order AUC monotonically.
- [MEASURED] The 5%-label experiment reports a larger mean CENTROID advantage than the full-label experiment.

[INFERRED] These are workshop-relevant observations. They do not establish the broader claims that guidance generally helps, anatomical precision generally does not, or location beats shape. The anatomy contrast is confounded, geometry uses only four arm-level points, the low-label analysis changes probe protocol, and all pretraining comparisons remain `n=1`.

## Is a roughly 0.011-AUC headline credible at n=1?

[INFERRED] It is credible as a fixed-encoder, fixed-test-set observation. It is not credible as an expected method effect.

[MEASURED] The test-subject interval excludes zero and probe-seed noise is reported as smaller than the gap. [MEASURED] No measurement bounds stochastic continuation variance. [MEASURED] The alternate probe optimizer reduces the full-label CENTROID margin to `+0.0038`. [INFERRED] The headline therefore lacks both pretraining replication and evaluator robustness.

## Effect of the self-reported defects on trust

[INFERRED] The disclosures increase trust in the authors’ willingness to report unfavorable findings.

[MEASURED] The paper withdraws the intended COVER interpretation, reports the collation mechanism, acknowledges `n=1`, discloses adaptive test reuse, and records that anatomy and rectangle arms are collated differently.

[INFERRED] Confidence in the experimental infrastructure nevertheless decreases. The logger measured COVER’s intent rather than delivered masks, the cross-family comparison was not controlled as advertised, excluded runs and precision settings required repeated correction, and several fixes were applied only to some occurrences. The net effect is greater trust in author candor but lower trust in the current manuscript as a coherent controlled experiment.

## Calibrated acceptance probability

**[INFERRED] 18%.**

[INFERRED] The trend is **18% -> 34% -> 22% -> 15% -> 18%**. The clean PDF, CENTROID rename, genuine epoch-75 result, and new clinical appendices recover some probability from the blind review. The rebound is limited by selective stopping, the still-unreplicated central effect, incomplete integration of the new anatomy result, persistent internal contradictions, and the newly exposed dependence of the headline on probe-fitting protocol.

## Single highest-value remaining fix

[INFERRED] Re-run the label-efficiency analysis using the exact primary frozen-probe optimizer, schedule, validation selection, and stopping rule, preserving and reporting repeat-level paired differences. Alternatively, re-evaluate every primary arm under the label-efficiency optimizer and use that common robust protocol for the headline.

[INFERRED] This takes priority because the current appendix changes the full-label CENTROID–RANDOM margin from `+0.0109` to `+0.0038` and moves COVER from `0.8577` to `0.8785`. Until that discrepancy is explained, the surviving “guidance helps” contribution is not stable to the paper’s own second linear-probe implementation.